Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What's The Winning Strategy In China? Franchises Are Key

This article was originally published in PharmAsia News

Executive Summary

Despite increasing concerns over protectionist policies in China, Morgan Stanley believes that market-based choices will trump government policies during the next decade, leading to success for multinational companies over the long term in the world's fastest-growing market

You may also be interested in...



J&J Opens Device R&D Center In China For Growing Rural Market

SHANGHAI - Johnson & Johnson and its device company in China Johnson & Johnson Medical (Suzhou) Ltd. will open a new innovation center in Suzhou to develop medical devices and diagnostic products for emerging markets in Asia

J&J Opens Device R&D Center In China For Growing Rural Market

SHANGHAI - Johnson & Johnson and its device company in China Johnson & Johnson Medical (Suzhou) Ltd. will open a new innovation center in Suzhou to develop medical devices and diagnostic products for emerging markets in Asia

Fidelity Growth Partner Asia's Norman Chen On Being An Active Investor In China: An Interview With PharmAsia News (Part 2 of 2)

Fidelity Growth Partners Asia has made its name on several blockbuster investments in China. In the IT sector, Fidelity invested in Alibaba, China's leading e-commerce company. In healthcare, Fidelity was an early investor in China's leading CRO WuXi AppTec Inc. and remains one of its largest shareholders.

Related Content

Latest News
UsernamePublicRestriction

Register

SC073443

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel